Trade Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a U.S. biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotechnology companies to use a clear strategy to design a rational drug rather than a fusion chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, near Oxford, England. Vertex was founded in 1989 by Joshua Boeger and Kevin J. Kinsella.The beginnings of kinsella.The company's beginnings were identified by Barry Firth in his 1994 book, The Billion Dollar Molecule, which was further developed in his 2014 book, Antidote: Inside the New Pharma.By World of 2004, his product pipeline focused on viral and autoimmune infections, inflammatory immune disorders, cancer, and cancer. In 2009, the company had about 1,800 employees, including 1,200 in the Boston area. By 2019, there were about 2,500 employees. Since late 2011, Vertex has been ranked among the top 15 performers in the S&P 500. Vertex shares rose 250 per cent in the same period. In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and headquartered in a new $800 million complex. Located on the waterfront of South Boston, this was the first time in the company's history that all of Vertex's approximately 1,200 employees in the Greater Boston area worked together. On January 23, 2019, Ian Smith, Operations Manager and Interim Chief Financial Officer of Vertex, was dismissed for undeclared personal conduct that violated the company's rules of conduct. In June. The same year, Vertex announced that it would acquire Exonics Therapeutics for up to $1 billion and collaborate with CRISPR Therapeutics, promoting its development to treat Duchenne muscular dystrophy and type muscular dystrophy 1.In September 2019 the company announced that it would receive Semma treatment for $950 million in cash. Semma Therapeutics has created "a small implantable device that carries millions of alternative beta cells, allowing glucose and insulin through while maintaining immune cells." On April 1, 2020, the former Chief Medical Officer, Rishma Kyoramani, became President and CEO of Vertex Pharmaceuticals. Former CEO and President Jeffrey Leiden moved to ceo, effective April 1, 2020. Dr. Leiden will serve as CEO until April 2023.